Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immatics ( (IMTX) ) has issued an update.
On May 12, 2026, Immatics filed a Form 6-K with the U.S. SEC and released an unaudited interim report for the three months ended March 31, 2026, along with its first-quarter financial results and business update. The filing incorporates the interim financials into multiple existing shelf and employee share registration statements, underscoring the company’s intent to keep its capital markets documentation current and to maintain flexibility for future equity-related activities.
The interim statement shows first-quarter 2026 revenue from collaboration agreements falling to €7.6 million from €18.6 million a year earlier, while research and development spending rose to €59.2 million and general and administrative costs increased to €14.5 million. Net loss widened to €57.8 million from €39.9 million, although a positive financial result of €8.3 million partly offset heavier operating losses, highlighting the ongoing capital-intensive nature of Immatics’ oncology pipeline and the earnings volatility tied to collaboration and financial income.
The most recent analyst rating on (IMTX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
The score is held back primarily by weak and volatile financial performance—especially ongoing cash burn and the sharp 2025 downturn—despite a comparatively strong, low-leverage balance sheet. Technicals are broadly neutral and do not offset the fundamental risk, while valuation support is limited given losses and no dividend.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. is a Germany-based biopharmaceutical company focused on developing T-cell–redirecting immunotherapies for cancer, leveraging platforms such as ACTengine and TCER to target tumor-specific antigens. The group operates through its German and U.S. subsidiaries, preparing its consolidated financial statements under IFRS and reporting in euros for global investors.
Average Trading Volume: 452,264
Technical Sentiment Signal: Buy
Current Market Cap: $1.52B
Learn more about IMTX stock on TipRanks’ Stock Analysis page.